Načítá se...
The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) effectively lower plasma glucose (PG) concentration in patients with type 2 diabetes, but studies have suggested that circulating glucagon concentrations and endogenous glucose production (EGP) are increased by SGLT2i, possibly compromising their gl...
Uloženo v:
| Vydáno v: | Diabetes |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Diabetes Association
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7679772/ https://ncbi.nlm.nih.gov/pubmed/33004472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db20-0369 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|